With the increasing recognition of the importance of genetic disease in horses, and the development of new technologies such as whole genome sequencing, there is an increased commercial interest in the rapid development and marketing of genetic tests for horses. While whole genome sequencing can pinpoint genetic variations associated with specific disease risk, it also can identify many dozens of genetic alleles (gene variations) with predicted effects that may or may not actually cause disease. Researchers will closely scrutinize currently marketed genetic tests for type 2 polysaccharide storage myopathy (PSSM2), myofibrillar myopathy (MFM) and recurrent exertional rhabdomyolysis (RER). This new information will ensure the validity of available screening tests and help veterinarians and horse owners make informed health decisions for horses with muscle diseases.
Grant amount awarded
University of Minnesota
Molly E. MCue, DVM, PhD, DACVIM-LAIM